发明名称 |
Induction of mucosal tolerance to antigens |
摘要 |
The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of Foxp3+ and/or IL-10 and/or TGF-β producing regulatory T-cells, capable of suppressing undesired immune responses toward an antigen, by oral delivery of said antigen in combination with an immunosuppressing cytokine secreting micro-organism. |
申请公布号 |
US9539291(B2) |
申请公布日期 |
2017.01.10 |
申请号 |
US201414216887 |
申请日期 |
2014.03.17 |
申请人 |
INTREXON ACTOBIOTICS NV |
发明人 |
Rottiers Pieter;Snoeck Veerle |
分类号 |
A61K35/74;A61K35/747;A61K38/20;A61K39/00;A61K39/39;A61K39/35;A61K39/395;A61K36/064 |
主分类号 |
A61K35/74 |
代理机构 |
Drinker Biddle & Reath LLP |
代理人 |
Drinker Biddle & Reath LLP |
主权项 |
1. A medicament, nutraceutical, or medical food for treating and/or alleviating type I diabetes or for inducing immune tolerance to type I diabetes comprising a beta cell autoantigen in type I diabetes and an IL-10 secreting Lactococcus lactic. |
地址 |
Zwijnaarde BE |